Approval · Notice of Compliance 28312 · 2022
ELAVIL: Notice of Compliance 28312
Issued June 2, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28312
- Date
- June 2, 2022
- Company
- AA Pharma Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Conversion of the Product Monograph to the new master template format.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ELAVIL | Not yet assigned | — |
Medicinal ingredients
- AMITRIPTYLINE HCL 10 MG per TAB
- AMITRIPTYLINE HCL 25 MG per TAB
- AMITRIPTYLINE HCL 50 MG per TAB
- AMITRIPTYLINE HCL 75 MG per TAB